ArticleProceedings of the National Academy of Sciences of the United States of America2018
Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation.
Registry-linked trialAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07509749 (Prospective Randomized Controlled Trial of Novel Therapies for Severe Acute GVHD), which is not on this map. Cited by 51 papers.
0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Randomized Controlled Trial of Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease)
Who cites it
51 citing papers in PubMed, 75 citations in OpenAlex.
- Trial
- Ruxolitinib plus steroids for acute graft versus host disease: a multicenter, randomized, phase 3 trial.Signal transduction and targeted therapy · 2024Trial
- Targeting Aurora kinase A to prevent GVHD and relapse after myeloablative allogeneic hematopoietic cell transplantation.Blood advances · 2026Article
- JAK1/2 Inhibition Delays Cachexia and Improves Survival through Increased Food Intake.bioRxiv : the preprint server for biology · 2025Article
- Chronic Graft-versus-host Disease, Part 2: Clinical Success and Roadmap to the Future.Transplantation · 2025Review
- Optimal GVHD Prophylaxis.Advances in experimental medicine and biology · 2025Review
- Cyclosporine and fedratinib combination therapy via modulating Th17/Treg balance in Rat model of membranous glomerulonephritis.Biochemistry and biophysics reports · 2024Article
- The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis.Annals of hematology · 2024Review
- Curcumin alleviated dextran sulfate sodium-induced colitis by recovering memory Th/Tfh subset balance.World journal of gastroenterology · 2023Article
- JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte-endothelial proadhesive interactions.Journal of thrombosis and haemostasis : JTH · 2023Article
- Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- The Absence of IL-12Rβ2 Expression on Recipient Nonhematopoietic Cells Diminishes Acute Graft-versus-Host Disease in the Gastrointestinal Tract.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Dissecting the regulatory network of transcription factors in T cell phenotype/functioning during GVHD and GVT.Frontiers in immunology · 2023Review
- Article
- S1P/S1PR1 signaling differentially regulates the allogeneic response of CD4 and CD8 T cells by modulating mitochondrial fission.Cellular & molecular immunology · 2022Article
- JAK2 gene knockout inhibits corneal allograft rejection in mice by regulating dendritic cell-induced T cell immune tolerance.Cell death discovery · 2022Article
- Dual JAK2/Aurora kinase A inhibition prevents human skin graft rejection by allo-inactivation and ILC2-mediated tissue repair.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022Article
- COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy.Frontiers in medicine · 2022Review
- Emerging translational strategies and challenges for enhancing regulatory T cell therapy for graft-versus-host disease.Frontiers in immunology · 2022Review
- Retention of Donor T Cells in Lymphohematopoietic Tissue and Augmentation of Tissue PD-L1 Protection for Prevention of GVHD While Preserving GVL Activity.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 5 institutions in 2 countries.
Brian C BettsDepartment of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL 12902; brian.betts@moffitt.org yux@musc.edu.
David BastianDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425.
Supinya IamsawatDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425.
Hung NguyenDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425.ORCID 0000-0001-9416-5137
Jessica L HeinrichsDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425.
Yongxia WuDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425.
Anusara DaenthanasanmakDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425.
Anandharaman VeerapathranDepartment of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL 12902.
Alison O'MahonyBioSeek, DiscoverX, South San Francisco, CA 94080.
Kelly WaltonDepartment of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL 12902.
Jordan ReffDepartment of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL 12902.
Pedro HornaDepartment of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL 12902.
Elizabeth M SagatysDepartment of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL 12902.
Marie C LeeDepartment of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL 12902.
Jack SingerCTI BioPharma, Seattle, WA 98121.
Ying-Jun ChangInstitute of Hematology, Peking University People's Hospital, Beijing, China.
Chen LiuDepartment of Pathology and Laboratory Medicine, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ 08901.
Joseph PidalaDepartment of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL 12902.
Claudio AnasettiDepartment of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL 12902.
Xue-Zhong YuDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425; brian.betts@moffitt.org yux@musc.edu.
Moffitt Cancer Center · USMedical University of South Carolina · USCTI BioPharma (United States) · USPeking University · CNRutgers, The State University of New Jersey · US
Funding
TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5MTargeting T-cell costimulation and cytokine activation to prevent GVHD and preserve GVLR01HL133823 · NHLBI · UNIVERSITY OF MINNESOTA · PI BETTS, BRIAN C · 2016 to 2020
$2.2MTargeting IL-12/23 p40 Pathways for the Control of GVHDR01CA169116 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI YU, XUE-ZHONG · 2013 to 2017
$1.6MTh1/Th17 Cell Differentiation in GVHD and GVLR01CA143812 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI YU, XUE-ZHONG · 2010 to 2013
$1.3MJAK2_STAT3 as a therapeutic target and marker of graft-versus-host diseaseK08HL116547 · NHLBI · H. LEE MOFFITT CANCER CTR & RES INST · PI BETTS, BRIAN C · 2013 to 2017
$691kNCI NIH HHS P30 CA076292NCI NIH HHS R01 CA143812NCI NIH HHS R01 CA169116NHLBI NIH HHS K08 HL116547NHLBI NIH HHS R01 HL133823
Abstract
Janus kinase 2 (JAK2) signal transduction is a critical mediator of the immune response. JAK2 is implicated in the onset of graft-versus-host disease (GVHD), which is a significant cause of transplant-related mortality after allogeneic hematopoietic cell transplantation (allo-HCT). Transfer of JAK2
Indexed as
Cell DifferentiationAnimalsFemaleGraft vs Host DiseaseGraft vs Leukemia EffectJanus Kinase 2Lymphocyte ActivationMaleMiceMice, Inbred BALB CMice, Inbred C57BLMice, Inbred NODMice, KnockoutMice, SCIDPrimary MyelofibrosisSkin TransplantationJak2 protein, mouseJanus Kinase 2graft rejectionGVHDGVLJAK2
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT07509749ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.